• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Life Sciences
  • Investments
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage

OurCrowd Launches $100M Pandemic Innovation Fund to Invest in Companies on Front Lines of COVID-19

by Fred Pennic 06/02/2020 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print
OurCrowd Launches $100M Pandemic Fund to Target Solutions for COVID-19

What You Should Know:

– Israeli venture capital platform OurCrowd launches $100M Pandemic Fund to invest in companies on the front lines of COVID-19.

– The fund plans to raise $100M to invest in 15-20 companies focused on prevention & containment, treatment & healing, and community & disruption mitigation technology solutions to combat current and future pandemic.


OurCrowd, a Jerusalem, Israel-based crowdfunded-venture investment platform, today announced the launch of its Pandemic Innovation Fund. The Fund plans to raise $100 million to invest in a target of 15-20 companies in urgent technological solutions for the medical, business, educational and social needs triggered by global pandemics and other health emergencies.

Investment Thesis

As humanity unites to fight the Coronavirus Crisis, the Fund will role support those on the front lines of COVID-19 while also funding companies poised to address the secular shifts in the economy that will arise in the post-pandemic world. The Fund aims to realize long-term capital appreciation for its investors by providing investment opportunities mainly in Israeli and Israeli-related companies that enable technology for (i) pandemic prevention and containment, (ii) pandemic treatment and healing and (iii) continuity and disruption mitigation.

Pandemic Fund Investment Focus

OurCrowd’s Pandemic Innovation Fund will invest in a broad mix of critical medical and non-medical sectors:

Prevention & Containment – Early detection & sensors, Vaccines, Testing, Personal protection, etc.

Treatment & Healing – Therapeutics, Diagnostics, Remote monitoring, Telehealth, Digital health, Health record portability

Continuity & Disruption Mitigation – Remote working, Distance learning, Robotic process automation, Home exercise, Cybersecurity, etc.

The Fund will both invest in new startups and select relevant companies already included in OurCrowd’s existing portfolio.

Existing Portfolio

OurCrowd’s portfolio already has more than 20 companies actively working to mitigate the coronavirus crisis and its effects, some of which will be candidates for follow-on investment from the Pandemic Investment Fund. OurCrowd’s existing investments in technologies on the frontlines of coronavirus response include:

MigVax – Developing the MigVax-101 COVID-19 oral subunit vaccine for humans based on a proven platform developed over 4 years that was shown to be a highly effective oral vaccine against IBV (Infectious Bronchitis Virus) in poultry  

Sight Diagnostics – Compact complete blood count analyzer that provides lab-grade results with 2 drops of finger prick blood sample in under 10 minutes

SaNOtize – Approved by Health Canada for multi-center Phase II trial of its Nitric Oxide Releasing Solution (NORSTM) for the prevention and early treatment of COVID-19

TytoCare – Remote physical exams and monitoring for primary care, chronic care and COVID-19 patients, protecting medical staff and reducing the burden on health systems

MeMed – Provides diagnostic insights to distinguish between bacterial and viral infections and is working on actionable solutions to help enable early intervention, before the onset of COVID-19 symptoms, and the implementation of measures to identify infection severity and improve patient management

Techsee – Remote Visual Assistance powered by Computer Vision AI & AR used by leading brands like Vodafone and Verizon to provide uninterrupted tech support while ensuring safety of employees and customers under social distancing

Kryon – Robotic process automation used to transfer and verify millions of coronavirus test results with individual patient health records in a fraction of the normal time 

Intuition Robotics – ElliQ AI-powered intelligent digital companion for the elderly, helping them stay sharp, connected and engaged

Zebra Medical Vision – Zebra-Med’s AI automatically detects and quantifies suspected COVID-19 findings on standard chest CTs, both contrast and non-contrast, and is already integrated in Apollo Hospitals Group in India

Advisors to the Fund, portfolio company experts, and top speakers from around the world will participate in the OurCrowd Pandemic Innovation Conference – an online event on June 22, 2020, broadcast from Jerusalem.

Pandemic Fund Management Team

The Fund’s general partners are:

Morris Laster – Healthcare executive with over 30 years’ experience in the biopharmaceutical industry, an expert in the identification, development, management, and financing of biomedical technologies who has founded six companies that have gone public.

Morry Blumenfeld – Venture Partner and Chairman of the Medical Advisory Board at OurCrowd, with a distinguished 30+ year career in medical innovation at GE Medical Systems.

David Sokolic – OurCrowd Venture Partner, 20+ year career at startups, technology leaders, and VC funds including, Microsoft, Radvision, and Battery Ventures.

“Together we must tackle the current pandemic as well as plan for future ones, because this story is just beginning. Entrepreneurs are uniquely skilled to provide fast and effective solutions to some of our greatest challenges. Our new fund will create the bridge between the innovations we need and the far-sighted investors able to provide the resources required to improve our world,” Dr. Morris Laster, Fund Partner said.

Availability to Investors

The fund is open to both accredited private investors (minimum $50,000) and institutional investors (minimum $1,000,000) and further information about this opportunity is available at www.ourcrowd.com.

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: Advisory Board, AI, biopharmaceutical, chronic care, Coronavirus (COVID-19), Cybersecurity, digital health, Health Systems, Healthcare Venture Capital, Medical Innovation, Microsoft, OurCrowd, Partners, Primary Care, Robotic Process Automation, sensors, TytoCare, venture capital, Zebra Medical Vision

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Interview

Reach7 Diabetes Studios Founder Chun Yong on Reimagining Chronic Care with a Concierge Medical Model

Most-Read

HHS Finalizes HTI-4 Rule: Prior Authorization & E-Prescribing Interoperability

HHS Finalizes HTI-4 Rule: Prior Authorization & E-Prescribing Interoperability

Meaningful Use Penalties_Meaningful Use_Partial Code Free_Senators Urge CMS to Establish Clear Metrics for ICD-10 Testing

CMS Finalizes TEAM Model: A New Era of Value-Based Surgical Care

White House Event Unveils CMS Health Tech Ecosystem Initiative

White House Event Unveils CMS Health Tech Ecosystem Initiative

Digital Health Faces Q2'25 Pullback: Funding Falls to 5-Year Low, But AI Dominates and $1B+ IPOs Emerge

Healthcare Investment Shifts in 1H 2025: AI Remains a Bright Spot Amidst Fundraising Decline

Digital Health Faces Q2'25 Pullback: Funding Falls to 5-Year Low

Digital Health Faces Q2’25 Pullback: Funding Falls to 5-Year Low

Beyond the Hype: Building AI Systems in Healthcare Where Hallucinations Are Not an Option

Beyond the Hype: Building AI Systems in Healthcare Where Hallucinations Are Not an Option

Health IT Sector Navigates Policy Turbulence with Resilient M&A

Health IT’s New Chapter: IPOs Return, Resilient M&A, Valuations Rise in 1H 2025

PwC Report: US Medical Cost Trend to Remain Elevated at 8.5% in 2026

PwC Report: US Medical Cost Trend to Remain Elevated at 8.5% in 2026

Philips Launches ECG AI Marketplace, Partnering with Anumana to Enhance Cardiac Care with AI-Powered Diagnostics

Philips Launches ECG AI Marketplace, Partnering with Anumana to Enhance Cardiac Care with AI-Powered Diagnostics

WeightWatchers Emerges from Bankruptcy, Launches New Menopause Program

WeightWatchers Emerges from Bankruptcy, Launches New Menopause Program

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |